NCT06560463Recruiting
Continuous Glucose Monitoring and OGTT Screen for Cystic Fibrosis Related Diabetes in Cystic Fibrosis
Comparison of Continous Glucose Monitor and OGTT as a Screen for Cystic Fibrosis Related Diabetes and Impaired Glucose Tolerance
Source: ClinicalTrials.gov · Last updated 31 Jul 2026
Brief summary (registry, in English)
Cystic Fibrosis (CF) related diabetes (CFRD) is a unique form of diabetes mellitus, different from type 1 diabetes and type 2 diabetes. The diagnosis of CFRD is associated with a decline in pulmonary function, decreased nutritional status, and increased mortality. CFRD is extremely common in people with CF, occurring in approximately 40-50% of adults with CF. Impaired glucose tolerance or dysglycemia is also very common in CF. It is standard of care to screen for CFRD annually from the age of 10 years with a two-hour Oral Glucose Tolerance Test (OGTT) with 75 g dextrose. The gold standard screening for CFRD is the OGTT which is problematic as it is time consuming for patient and staff and adherence to annual screening is low among CF centers. Survival has improved dramatically with the advent of CFTR modulators and it is presumed that the incidence of CFRD will increase with increased life expectancy. The Cystic Fibrosis Foundation (CFF) has developed the oldest disease specific patient registry, consisting of approximately 35000 patients, so there is vast historical information available on individual patients and larger datasets on the CF community as a whole. Based on the 2021 CFF patient registry data, the current life expectancy for CF patients born between 2017 and 2021 is 53 years - a 15 year increase from a decade ago.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 30 (estimated)
- First submitted
- 2 Jul 2024
- Start date
- 13 Jan 2025
- Primary completion date
- 1 Sept 2027
- Lead sponsor
- Medical College of Wisconsin
- Diseases
- Cystic fibrosis
- NCT number
- NCT06560463
What you commit to
- Study type: Observational
- Planned participants: 30
- From 13 Jan 2025 to the primary completion date, 1 Sept 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Diagnosed with CFRD and treating with diabetogenic medications.
- s/p transplant
Other illness
- failure to wear CGM for entirety of 10 days
Other
- pregnancy
Who the study is looking for
- An adult patient, diagnosed with CF, established with Froedtert Multidisciplinary CF Clinic.
- Normal glucose tolerance or impaired glucose tolerance per OGTT completed in 2024.
- At healthy baseline status at time of CGM wear and OGTT.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Medical College of Wisconsin Coordinator of this site? Confirm its status | Milwaukee | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.